Skip to main content
NEOG logo

NEOG · Neogen Corp

Track NEOG — free
$10.80 -0.08 (-0.74%)
Market Cap
$2.38B
Shares
218.31M
Volume · Nov 16 2.39M Avg daily vol (3M) 3.44M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.88 Open$11.07 Day$10.83–11.25 52W close$5.41–13.98 Avg vol 30d3.6M Short int12.7M · 5.8% of shares · 4.8d Short vol78% Last earningsOct 6, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 7

Up next

Jan 7, 2027 Est · unconfirmed · in 7 wks

Latest documents

2026
Oct 26
Current report 8-K/A Events of Oct 1
Director or officer change, or executive pay

Neogen Corporation shareholders approved its Amended and Restated Omnibus Incentive Plan on October 1, 2026, authorizing equity-based awards and up to 31,350,000 shares.

Oct 7
Investor event
Investor Day

Neogen reported positive core growth for four consecutive quarters and strategic accounts up 6.2 percent year to date, targeting eight plus percent by year end. Its strategy centers on commercial prowess, high-impact innovation and operational excellence.

Read from the first part of this long document
Oct 7
Quarterly report 10-Q FY2027 Q1, ended Aug 31
Quarterly report for FY2027 Q1

Neogen Corporation reported $13.6 million revenue growth and 47.4% gross margin for the three months ended August 31, 2026; the Genomics sale remained under ACCC and NZCC review expected to conclude by the end of December 2026.

Revenue $222.8M ▲ 6.5% Net loss $11.9M Diluted EPS -$0.05
Read from the MD&A section
Oct 7
Current report 8-K Events of Oct 1
Shareholder vote results

Neogen Corporation shareholders approved executive compensation, ratified BDO USA, P.C., and approved the amended incentive plan and an Employee Stock Purchase Plan amendment increasing shares available for issuance at the 2026 Annual Meeting.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$884.00M
Trailing 12 months
Net income (TTM)
−$56.12M
Trailing 12 months
Revenue growth YoY
+6.5%
Year over year
Operating margin
-0.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
2.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$608.20M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.4%
Year over year · more shares
Price change (1Y)
+70.3%
Trailing year
Short interest
5.8%
Latest settlement · 4.8 days to cover
View all 125 metrics

AI Brief

Q4 FY26 earnings call · Jul 30, 2026
Q4 FY26

TL;DR. Neogen reported Q4 FY26 core revenue growth of 4.3% led by Food Safety at 5.8% core growth, its highest since FY23, with adjusted EBITDA of $45.4 million (20.2% margin) and free cash flow of $26.2 million; the company provided FY27 guidance of $880-$885 million revenue and $180-$182 million adjusted EBITDA while planning a 50% R&D increase, a Petrifilm manufacturing transition starting November 2026, and the Petrifilm first SKU validation by end of August.

Bullish
  • + Q4 Food Safety core growth of 5.8%, highest since FY23, with Bacterial & General Sanitation up 9.9% and Indicator Testing/Culture Media up 9.5%
  • + Adjusted gross margin expanded 330 bps year-over-year to 49.7%
  • + FY27 revenue guidance of $880-$885 million implies ~3% core growth and adjusted EBITDA of $180-$182 million, with management noting $30 million above prior street consensus
  • + Inventory reduced by more than $36 million year-over-year and on-time/full delivery improved 40% since launching SNOP
  • + R&D investment increasing ~50% in FY27 with long-term objective of approaching 5% of revenue
Bearish
  • − FY27 reported revenue growth implication is only ~1.5% after ~50 bps divestiture headwind and ~100 bps negative FX
  • − FY27 adjusted EBITDA margin of 20.5% at midpoint implies only slight expansion vs FY26 as investments absorb efficiencies
  • − Customer inflation pressures from Iran war temper near-term volume outlook despite positive industry volume trends
  • − FY27 transformation initiatives expected to total $25 million, up from ~$22 million in FY26
  • − Genomics divestiture regulatory review moved into second phase in Australia and New Zealand, extending closing timeline risk

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg −11%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 64%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return +18%
trailing
YTD return +56%
this year
Relative strength +20%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +52 funds added
Insider flow Distributing
Net -$108.6K over 90 days · 50% sells
Short interest Rising
5.82% of shares out · ▲ +6.5% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
324 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Strong
Revenue growth −3%
Y/Y
Gross margin 47%
contracting
EPS growth +99%
Y/Y
Free cash flow $81.7M
Balance sheet $608.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 58%
annualized · 1-yr
Max drawdown −28%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the 8-K filed Oct 6, 2026
Revenue · fiscal year 2027 $885M – $890M
prior FY $870.4M midpoint +2.0% Y/Y
Adjusted EBITDA · fiscal year 2027 Non-GAAP $181M – $183M
Previous outlook earlier release · from the 8-K filed Jul 30, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA · fiscal year 2027 $13M
Core growth · fiscal year 2027 3%
Prior guidance period ended · from the 8-K filed Jul 30, 2026
Total revenue · first quarter of fiscal year 2027 $207M – $209M
Adjusted EBITDA · first quarter of fiscal year 2027 $37M
Guided vs delivered · last 4 settled
Total revenue first quarter of fiscal year 2027
guided $207M – $209M
$222.8M Beat +7.1%
Revenue full-year fiscal year 2026
guided $845M – $855M
$870.4M Beat +2.4%
Revenue full year fiscal year 2025
guided $925M – $955M
$894.7M Miss −4.8%
Revenue full-year
guided $910M – $920M
$924.2M Beat +1.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
−11% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
64% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +52 funds added
Insider flow Distributing
Net -$108.6K over 90 days · 50% sells
Short interest Rising
5.82% of shares out · ▲ +6.5% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
324 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $11 · 64% Range high $14
vs 200-day avg +3% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash flow from operations $12.9M Q1 FY2027 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities $12.9M
-$8.2M Purchases of PPE
= Free Cash Flow $4.7M
Animal Safety Core Revenue Growth non-GAAP 0.5% Q4 FY26 —
Food Safety Core Revenue Growth non-GAAP 3.1% FY26 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NEOG
Neogen Corp
this stock
$2.38B +55.7% -2.7% — 5.8%
ABT
Abbott Laboratories
$186.10B -14.2% +5.7% 40.1 1.1%
MDT
Medtronic plc
$131.60B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$118.29B -11.6% +11.2% 33.1 1.7%
BSX
Boston Scientific Corp
$63.33B -54.2% +12.5% 18.5 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
324
% held
96.0%
Net QoQ
-27.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
288
View
Short & Settlement
Short Interest Rising
Shares short
12.7M
Days to cover
4.8d
Change
+781.0K sh
View
Short Volume
Short vol %
78%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
596
Value
$7.1K
As of
Oct 23, 2026
View
Off-Exchange
Off-exchange %
34.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$108.6K
Buyers / Sellers
1 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$870.4M
Net income (FY)
$-7.9M
EPS diluted
$-0.04
View
Buybacks
Authorized
shares 6.0M
Remaining
shares 5.9M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
19
View
Proposed Sales
Value
$114.6K
Shares
9.1K
Filed
Nov 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 7, 2026
View
Investor Relations
Latest news
Neogen® To Participate in 2026 UB…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
NEOG -9.9% -6.5% +18.3% -8.0% +55.7%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -8.2% -3.0% +19.7% -5.9% +47.1%

Capital returns

Buyback program · as of May 31, 2022
Authorized
shares 6.00M
Spent (derived)
shares 100,000
Remaining
shares 5.90M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 711377 CUSIP 640491106 13F (30d) 336 filings 307 filers Visit website Investor relations